Inhibition of rat brain histamine-N-methyltransferase by 9-amino-1,2,3,4-tetrahydroacridine (THA).
9-Amino-1,2,3,4-tetrahydroacridine (THA), an inhibitor of acetylcholinesterase, has been proposed as a treatment for Alzheimer's disease on the basis of its ability to increase cerebral levels of acetylcholine. THA shares structural features with aminoquinoline compounds known to be inhibitors of histamine-N-methyltransferase (HNMT). THA was found to be a potent competitive inhibitor of rat brain HNMT in vitro, with a Ki of 35 nM with respect to both histamine and S-adenosyl-L-methionine, the co-substrate. Two hours after systemic administration of THA (5 and 10 mg/kg, i.p.), HNMT from rat brain was largely inhibited. The levels of histamine in striatum and cerebral cortex were elevated by this treatment. Thus, THA at moderate doses is able to alter histamine metabolism in the central nervous system.
Cumming
P
P
Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Colombia, Vancouver, Canada.
Reiner
P B
PB
Vincent
S R
SR
D015761:4-Aminopyridine / Q000494:pharmacology; D000609:Aminoacridines / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D006632:Histamine / Q000032:analysis / Q000378:metabolism; D006637:Histamine N-Methyltransferase / Q000037:antagonists & inhibitors*; D007274:Injections, Intraperitoneal; D008297:Male; D008780:Methyltransferases / Q000037:antagonists & inhibitors*; D010830:Physostigmine / Q000494:pharmacology; D011739:Pyrimethamine / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D013619:Tacrine / Q000494:pharmacology*
D000609:Aminoacridines; D000970:Antineoplastic Agents; C006308:metoprine; D013619:Tacrine; D006632:Histamine; D010830:Physostigmine; D015761:4-Aminopyridine; D008780:Methyltransferases; D006637:Histamine N-Methyltransferase; D011739:Pyrimethamine